Drug Trial Radar · NCT05035030
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
62
Actual
Start
Sep 3, 2021
Primary completion
Feb 15, 2027
Study completion Feb 15, 2027
Sponsor
- Lead sponsor
- Albireo, an Ipsen CompanyIndustry
- Sponsor type
- Industry
- First posted
- Sep 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the long-term safety and effectiveness of odevixibat in participants with Alagille syndrome (ALGS). The participants of this study will have ALGS a rare genetic disorder that can affect multiple organ systems of the body including the liver, heart, skeleton, eyes and kidneys. Common symptoms, which often develop during the first three months of life, include blockage of the flow of bile from the liver (cholestasis), yellowing of the skin and mucous membranes (jaundice), poor weight gain and growth and severe itching (pruritis). The drug used for the study is odevixibat and was authorized for the treatment of cholestatic pruritus in infants with ALGS over 12 months of age by the United States Food and Drug Administration on 13 June 2023.
Conditions
- Alagille Syndrome
Interventions
OdevixibatDrug
Odevixibat is a small molecule and selective inhibitor of IBAT.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in pruritusTime frame: Baseline to week 72 (cohort 1).
- Percentage of participants with Treatment Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)Time frame: Baseline to week 12 (cohort 2).
- Percentage of participants with clinically significant changes from baseline in Physical ExaminationTime frame: Baseline to week 12 (cohort 2).
- Percentage of participants with clinically significant changes in Laboratory ParametersTime frame: Baseline to week 12 (cohort 2).
- Percentage of participants with clinically significant changes from baseline in Vital Signs.Time frame: Baseline to week 12 (cohort 2).
- Change from baseline in concomitant medications.Time frame: Baseline to week 12 (cohort 2).
- Change from baseline in fat-soluble vitamin levels.Time frame: Baseline to week 12 (cohort 2).
Locations
35 sites in 10 countries. Site status is shown where the registry gives one.
Rady Children's Hospital
San Diego, California
UCSF
San Francisco, California
Children's Healthcare of Atlanta
Atlanta, Georgia
Riley Hospital for Children at IU Health
Indianapolis, Indiana
Johns Hopkins Hospital
Baltimore, Maryland
Boston Children's Hospital
Boston, Massachusetts
Children's Mercy Hospital and Clinics
Kansas City, Missouri
Northwell Health System
New Hyde Park, New York
Hassenfeld Children's Hospital at NYU Langone
New York, New York
New York-Presbyterian / Columbia University Irving Medical Center
New York, New York
The Childrens Hospital at Montefiore Albert Einstein School of Medicine
The Bronx, New York
Atrium Health Carolinas Medical
Durham, North Carolina
Cincinnati Children's Hospital
Cincinnati, Ohio
Oregon Health Science University School of Medicine
Portland, Oregon
Monroe Carell Jr. Childrens Hospital at Vanderbilt
Nashville, Tennessee
Childrens Medical Center of Dallas University of Texas Southwestern
Dallas, Texas
Texas Children's Hospital
Houston, Texas
Texas Liver Institute
San Antonio, Texas
Cliniques Universitaires Saint-Luc Bruxelles
Brussels, Belgium
Hôpital Femme Mère Enfant de Lyon
Bron, France
Antenne pediatrique du CIC-Hopital Jeanne De Flandre
Lille, France
Hopital Necker Enfants Malades
Paris, France
Charité - Universitätsmedizin Berlin
Berlin, Germany
Medizinische Hochschul
Hanover, Germany
Universitatsklinik fur Kinder-und Jugendmedizin Tubingen
Tübingen, Germany
AOU Meyer
Florence, Italy
Azienda Ospedale University
Padova, Italy
Ospedale Pediatrico Bambino Gesu
Rome, Italy
University of Malaya Medical Center
Kuala Lumpur, Malaysia
Universitair Medisch Centrum Groningen
Groningen, Netherlands
Wilhelmina Children's Hospital UMCU Utrecht
Utrecht, Netherlands
Instytut Pomnik-Centrum Zdrowia Dzieck
Warsaw, Poland
Istanbul University Istanbul Medical Faculty Hospital
Istanbul, Turkey (Türkiye)
Birmingham Women's and Children's NHS Foundation Trust
Birmingham, United Kingdom
King's College Hospital NHS Foundation Trust King's College Hospital Paediatric Research
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.